stockrowCelldex Therapeutics, Inc. (CLDX) vs Vericel Corporation (VCEL)
- Celldex Therapeutics, Inc. CLDX 29.89 +5.73%
- Vericel Corporation VCEL 53.64 +3.59%
Celldex Therapeutics, Inc. and Vericel Corporation are both Biotechnology companies. Vericel Corporation is the larger, with a market value of $2.7B against $2.2B — 1.2× the size. Celldex Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 77.8×. Vericel Corporation grew revenue faster over the last twelve months: 25.3% against −88.3%. Vericel Corporation has the higher net margin (10.3% vs −33,883.8%) and the higher return on invested capital (7.88% vs 0.00%). Across the 19 metrics below, Vericel Corporation leads on 16 and Celldex Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | CLDX | VCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 74.47% | 65.16% |
| Operating margin | (36,733.82%) | 8.32% | 0.00% |
| Net margin | (33,883.77%) | 10.27% | 0.00% |
| Free cash flow margin | (27,294.81%) | 17.86% | 0.00% |
| Return on equity | (43.88%) | 9.44% | (50.12%) |
| Return on assets | (40.76%) | 6.86% | (45.60%) |
| Return on invested capital | 0.00% | 7.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack